IRONWOOD PHARMACEUTICALS INC — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Thomas McCourt (CEO) and Ronald Silver (Interim CFO) signed standard Sarbanes-Oxley certifications on August 6, 2026 for the Q2 2026 10-Q ending June 30, 2026. Both officers certify financial statements fairly present the company's condition and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, significant deficiencies, or fraud involving management are disclosed.
Why this rating
Routine Sarbanes-Oxley certifications; no substantive business, financial, or control changes disclosed. Standard periodic filing requirement for public company.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.